Full-Time

In Vivo Specialist

In Vivo Studies

Posted on 9/3/2025

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Antibody discovery and licensing platform

Compensation Overview

CA$75.8k - CA$94.7k/yr

+ Equity + Annual Bonus + 6% RRSP Contribution

Vancouver, BC, Canada

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Extensive experience conducting *in vivo* studies in accordance with Animal Use Protocols and Standard Operating Procedures
  • Experienced with animal handling, dosing (IV, IP, SQ), and blood collection
  • Strong understanding of the 3Rs and research ethics
  • 6+ years of experience in an *in vivo* research environment
  • BSc, MSc, and/or experience with *in vitro* and *ex vivo* techniques are considered assets
  • Excellent communication, documentation, and organizational skills
  • Ability to lift up to 25 kg
  • Comfortable with long periods of standing and bending throughout the day
Responsibilities
  • Caring for multiple species and performing *in vivo* and *ex vivo* techniques to support *in vivo* studies
  • Preparing and aliquoting reagents required for *in vivo* studies
  • Overseeing *in vivo* day-of-study operations to ensure smooth execution and to maximize efficiency
  • Collaborating with study leads, scientists, and cross-functional teammates, ensuring alignment on study protocols, animal welfare considerations, and animal macro- and micro- environment requirements of *in vivo* studies
  • Ensuring accurate recording of *in vivo* data across all studies, and supporting teammates with data analysis as required
  • Providing technical support, troubleshooting, and problem-solving solutions, while identifying opportunities for process improvement and implementing best practices to optimize workflow efficiency
  • Contributing to the preparation of Animal Use Protocols (AUPs) and Standard Operating Procedures (SOPs) to comply with CCAC Regulations and Guidelines
  • Training and mentoring team members to ensure compliance with safety policies, SOPs, and regulatory requirements
Desired Qualifications
  • Self-motivated person
  • Fast learner
  • Team player
  • Creative problem solver
  • Ability to manage competing priorities in a collaborative, fast-paced work environment

AbCellera Biologics helps other companies and research teams find and develop antibody therapies. It uses a proprietary technology platform to identify antibody candidates and collaborates with pharmaceutical and biotech partners to accelerate drug discovery and development. The company's products are the antibody candidates and discovery services it provides under licensing or collaboration agreements, as well as its own internal therapeutic programs. Unlike many competitors, AbCellera emphasizes tackling difficult drug targets and building long-term partnerships with a wide range of clients, using data-driven, multidisciplinary approaches to speed up discovery. The goal is to deliver safe, effective antibody medicines to patients by advancing partner programs and its own pipeline through discovery, licensing, and development.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • ABCL635 Phase 1 succeeds with 24-day half-life, advances to Phase 2 efficacy in Q3 2026.
  • Q1 2026 revenue doubles to $8.3M, $655M liquidity funds three-year runway.
  • Stephen Quake joins board in 2026, bolstering single-cell and antibody expertise.

What critics are saying

  • Annual $120-130M burn exhausts $655M liquidity in 5 years without milestones.
  • ABCL635 Phase 2 fails superiority over Bayer's elinzanetant in Q3 2026.
  • ABCL575 Phase 1 uncovers T-cell safety issues, delays atopic dermatitis IND by 2027.

What makes AbCellera Biologics unique

  • AbCellera's GPCR platform yields ABCL635, first antibody for menopause hot flashes.
  • Proprietary engine discovers ABCL575, half-life extended anti-OX40L for atopic dermatitis.
  • T-cell engager platform expands AbbVie oncology collaboration beyond 2022 partnership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

1%

2 year growth

1%
Yahoo Finance
Apr 14th, 2026
Jones Trading initiates coverage of AbCellera as ABCL635 enters Phase 2 trial

Jones Trading has initiated coverage of AbCellera Biologics with a positive rating in early April 2026, highlighting the company's antibody-based medicines platform and advancing clinical programmes. The coverage focuses on AbCellera's transition to a clinical-stage model and expanding pipeline. The investment case centres on whether AbCellera's antibody discovery engine can translate into successful clinical assets, particularly ABCL635 and ABCL575, generating milestone and royalty revenue. A key near-term catalyst is clinical data for ABCL635 in menopause, expected in Q3 2026, following the programme's advancement to Phase 2 in January 2026. However, risks remain around continued net losses and uneven revenue as the company develops its own pipeline. Analyst views vary significantly, with pessimistic forecasts projecting 16% annual revenue decline versus more optimistic scenarios.

Yahoo Finance
Apr 2nd, 2026
AbCellera outlines biotech transition with $700M cash, Phase 2 hot flash treatment

AbCellera Biologics outlined its vision at the KeyBanc Capital Markets Healthcare Forum 2026, highlighting its transition to a mid- to late-stage biotech company. The firm reported a strong financial position with approximately $700 million in cash and a three-year runway supported by government funding, alongside an annual cash burn of $120 to $130 million. The company's pipeline includes ABCL635, currently in Phase 2 trials for non-hormonal treatment of hot flashes with potential cancer-related applications, and ABCL575 in Phase 1 testing for immunological diseases. On 24 February, AbCellera announced earnings per share of -$0.03, beating expectations of a $0.18 loss by 83.33%. Revenue increased by $39.80 million year-over-year.

Insider Monkey
Nov 18th, 2025
Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution?

Why wall street maintains buy stance on AbCellera Biologics Inc. (ABCL) amid business model evolution? Published on November 18, 2025 at 6:17 am by abdul rahman in news. AbCellera Biologics Inc. (NASDAQ:ABCL) is a must-buy penny stock to buy now. On November 13, at the Stifel 2025 Healthcare Conference, AbCellera Biologics Inc. (NASDAQ:ABCL) reaffirmed its strategic evolution into a company focused on developing clinical assets. The company will no longer operate under a partnership model but will develop its own assets backed by a strong financial position. With over $500 million in cash and equivalents, AbCellera is focused on the development of ABCL635, a first-in-class antibody medicine for the non-hormonal treatment of moderate to severe menopausal hot flashes. The company is also working on ABCL575, an antibody for the treatment of moderate-to-severe atopic dermatitis (AD). Even as the company continues to work on its clinical assets, strategic partnerships with big Pharma, including Eli Lilly and AbbVie, are crucial. The internal clinical assets are only seen as a presale activity for future licensing. Amid the new strategic focus, on November 7, TD Cowen analyst Brendan Smith reiterated a Buy rating, as Stifel Nicolaus analyst Stephen Wiley echoed similar sentiments with a Buy rating and a $7 price target. AbCellera Biologics Inc. (NASDAQ:ABCL) is a clinical-stage biotechnology company that discovers and develops antibody-based medicines for a range of diseases, including cancer, metabolic and endocrine conditions, and autoimmune disorders. While we acknowledge the potential of AbCellera Biologics Inc. (NASDAQ:ABCL) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about the cheapest AI stock. Disclosure: None. This article is originally published at Insider Monkey.

Business Wire
Nov 10th, 2025
AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera appoints Dr. Stephen Quake to its Board of Directors. VANCOUVER, British Columbia-(BUSINESS WIRE)-AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications. "We are pleased to welcome Dr. Quake to AbCellera's Board of Directors. His presence reinforces our commitment to excellence in science and technology," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "He brings a distinctive combination of scientific breadth, creativity, and interdisciplinarity that resonates with AbCellera's culture and strategy." Dr. Quake is currently the Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University and was previously the Thomas and Doris Everhart Professor of Applied Physics and Physics at Caltech. He has been elected to four U.S. national academies: the National Academies of Sciences, Engineering, Medicine, and Inventors. In 2025, Dr. Quake was elected as a Foreign Member of the Royal Society. Dr. Quake was the founding co-president of the Chan Zuckerberg Biohub starting in 2016 and later became president of the Chan Zuckerberg Biohub Network and Head of Science for the Chan Zuckerberg Initiative until 2025. Under his leadership, the Biohub had a launch budget of approximately $600 million and delivered on foundational large-scale science programs, including several whole organism Single Cell Atlases. As an entrepreneur, Dr. Quake has cofounded more than a dozen companies developing products in fields of microfluidics, genomics, molecular diagnostics, and therapeutics. "I greatly admire what Carl and the AbCellera team have accomplished to date, and I'm thrilled to join the team and be a part of it going forward," said Dr. Quake. Dr. Quake received a B.S. in Physics and M.S. in Mathematics from Stanford University and a doctorate in Theoretical Physics from the University of Oxford. Concurrent with Dr. Quake's appointment, Andrew W. Lo, Ph.D., will be resigning as independent director. Dr. Lo, a cofounder of BridgeBio Pharma and the Charles E. and Susan T. Harris Professor of Finance at the MIT Sloan School of Management, joined the Board in December 2021 and served on Audit and Nominating and Corporate Governance Committees. "It has been a pleasure to work with Andrew over the past four years. His guidance and unique financial insights have meaningfully contributed to advancing AbCellera's business and strategy," said Dr. Hansen. "Our team and board thank Andrew for his leadership and wish him the best in his future endeavors." AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com. Inquiries Media: Tiffany Chiu; [email protected], +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005 Investor Relations: Peter Ahn; [email protected], +1(778)729-9116 Source: AbCellera Biologics Inc. VANCOUVER, British Columbia-( BUSINESS WIRE )-AbCellera Reports Q3 2025 Business Results... VANCOUVER, British Columbia-( BUSINESS WIRE )-AbCellera to Participate at Upcoming Investor Conferences in November and December 2025... VANCOUVER, British Columbia-( BUSINESS WIRE )-AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025...

Business Wire
Sep 10th, 2025
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera appoints Dr. Sarah Noonberg as Chief Medical Officer.

INACTIVE